Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Check Point Software Technologies Ltd (CHKP) vs Heron Therapeutics Inc (HRTX) Price & Performance

Check Point Software Technologies LtdTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Check Point Software Technologies Ltd vs Heron Therapeutics Inc — how do they compare? Check Point Software Technologies Ltd trades at $128.43 (market cap $13.18B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Check Point Software Technologies Ltd is far larger — about 214.4× Heron Therapeutics Inc's market cap, and Check Point Software Technologies Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

CHKPHRTX
Market Cap
$13.18B$61.47M
Sector
TechnologyHealth
52-Week High
$206.91$1.49
52-Week Low
$112.47$0.32
Enterprise Value
$12.88B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Check Point Software Technologies Ltd

Check Point Software (CHKP) trades at $127.61, down 2.69% amid bearish technical signals, though it maintains strong fundamentals with a 37.93% net margin and consistent earnings beats. The company shows robust profitability with 86.12% gross margins and positive cash flow generation of $1.29B in 2025. Recent news highlights AI security growth potential and insider selling activity.

The stock presents a value opportunity with a 13.24 P/E ratio below industry averages, supported by analyst consensus target of $146.92 representing 15% upside. Key risks include competitive pressures in cybersecurity and margin compression trends. Institutional sentiment remains mixed with 41% buy ratings versus 51% hold recommendations.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Check Point Software Technologies Ltd

Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.

Read more on CHKP

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX